IPO Report: Sagimet Biosciences gives going public a second chance under new CEO

Biotech drug developer Sagimet Biosciences is taking another shot at going public, according to a filing with the SEC late Friday.

Previous post : Beauty shopping platform Oddity Tech files for IPO
Next post : As I-95 reopens, FedEx says section collapse has had ‘minimal’ impact on its operation